Which lung cancer patients are suitable for ceritinib/ceritinib?

Ceritinib is a selective, oral ALK tyrosine kinase inhibitor (ALK-TKI) designed to treat patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Although this type of patients does not account for a high proportion of the lung cancer population (about 3%-7%), due to their unique molecular targets, they can benefit significantly from targeted drug treatment. For patients with locally advanced or metastatic non-small cell lung cancer diagnosed as ALK-positive, ceritinib has become an important option after crizotinib, especially suitable for further management after failure of first-generation ALK inhibitor therapy.

So, which lung cancer patients are really suitable for ceritinib? The first thing to make clear is that the core indication of ceritinib is for patients who are positive for ALK gene rearrangement. This mutation is more common in lung adenocarcinoma subtypes, especially in non-smokers, young people, and female patients. In the context of unsatisfactory results from conventional chemotherapy, this group of people can give priority to ceritinib for targeted therapy after confirming ALK positivity through genetic testing.

Secondly, ceritinib is very suitable for patients who have failed crizotinib treatment. As a first-generation ALK inhibitor, crizotinib performs well in early tumor control, but over time, some patients will develop resistance. Common resistance mechanisms include ALK mutations, bypass activation or brain metastasis. As a second-generation drug, ceritinib is designed to have stronger ALK binding ability and broader coverage of drug-resistant mutations. It is especially superior to crizotinib in controlling brain metastases. Therefore, patients who have experienced disease progression after receiving crizotinib treatment are the key candidates for ceritinib.

In addition, ceritinib can also be used as a first-line option in the initial treatment phase, especially when patients are intolerant to crizotinib or have potential risk of drug resistance. In some international treatment guidelines, ceritinib has been listed as one of the optional first-line options for patients with ALK-positive NSCLC.

Reference materials:https://go.drugbank.com/drugs/DB09063